The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach

B. Ditz; J. Boekhoudt; N. Couto; C. A. Brandsma; P. S. Hiemstra; G. W. Tew; M. Neighbors; M. A. Grimbaldeston; W. Timens; H. A.M. Kerstjens; J. W.A. Rossen; V. Guryev; M. van den Berge; A. Faiz

doi:10.1080/15412555.2022.2033193

The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach

B. Ditz, J. Boekhoudt, N. Couto, C. A. Brandsma, P. S. Hiemstra, G. W. Tew, M. Neighbors, M. A. Grimbaldeston, W. Timens, H. A.M. Kerstjens, J. W.A. Rossen, V. Guryev, M. van den Berge, A. Faiz

Research output: Contribution to journal › Article › peer-review

1 Citation (SciVal)

Abstract

Current knowledge about the respiratory microbiome is mainly based on 16S ribosomal RNA gene sequencing. Newer sequencing approaches, such as metatranscriptomics, offer the technical ability to measure the viable microbiome response to environmental conditions such as smoking as well as to explore its functional role by investigating host-microbiome interactions. However, knowledge about its feasibility in respiratory microbiome research, especially in lung biopsies, is still very limited. RNA sequencing was performed in bronchial biopsies from clinically stable smokers (n = 5) and ex-smokers (n = 6) with COPD not using (inhaled) steroids. The Trinity assembler was used to assemble non-human reads in order to allow unbiased taxonomical and microbial transcriptional analyses. Subsequently, host-microbiome interactions were analyzed based on associations with host transcriptomic data. Ultra-low levels of microbial mass (0.009%) were identified in the RNA-seq data. Overall, no differences were identified in microbiome diversity or transcriptional profiles of microbial communities or individual microbes between COPD smokers and ex-smokers in the initial test dataset as well as a larger replication dataset. We identified an upregulated host gene set, related to the simultaneous presence of Bradyrhizobium, Roseomonas, Brevibacterium.spp., which were related to PERK-mediated unfolded protein response (UPR) and expression of the microRNA-155-5p. Our results show that metatranscriptomic profiling in bronchial biopsy samples from stable COPD patients yields ultra-low levels of microbial mass. Further, this study illustrates the potential of using transcriptional profiling of the host and microbiome to gain more insight into their interaction in the airways.

Original language	English
Pages (from-to)	81-87
Number of pages	7
Journal	COPD: Journal of Chronic Obstructive Pulmonary Disease
Volume	19
Issue number	1
Early online date	4 Feb 2022
DOIs	https://doi.org/10.1080/15412555.2022.2033193
Publication status	Published - 31 Dec 2022
Externally published	Yes

Bibliographical note

Funding Information:
HK reports unrestricted grants, from Boehringer Ingelheim, Novartis and GlaxoSmithKline. He also reports fees advisory board participation for AstraZeneca, Boehringer Ingelheim, Novartis and GlaxoSmithKline. All above paid to his institution. GWT reports and I am a full time employee of Genentech, Inc and hold stock and options in the Roche. PH reports grants from Boerhinger Ingelheim, grants from Galapagos, outside the submitted work; MAG reports I am full time employee of Genentech, Inc and hold stock and options in the Roche Group. WT reports personal fees from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, personal fees from Bristol-Myers-Squibb, personal fees from AbbVie, outside the submitted work. JR reports personal fees from IDbyDNA Inc., from null, from null, outside the submitted work; and Dr. Rossen is currently an employee of IDbyDNA. IDbyDNA did not have any influence on the interpretation of reviewed data and conclusions drawn, nor on the drafting of the manuscript, and did not (financial) support the study. MN reports I am a full time employee of Genentech, Inc and hold stock and options in the Roche Group. BD, JB, NC, CAB, VG, AF and MvdB have nothing to disclose.

Funding Information:
The submitted work is cofinanced by the Ministry of Economic Affairs and Climate Policy by means of the PPP. AF was supported by a junior longfond grant (4.2.16.132JO). The study was funded by unrestricted grants from the Stichting Astma Bestrijding, the Netherlands Asthma Foundation, Netherlands Organization for Scientific Research (ZonMw), GlaxoSmithKline, the Royal Dutch Academy of Sciences and Arts, the University Medical Center Groningen and Leiden University Medical Center and the NIH R01 HL095388 (Spira/Lenburg). RNA-sequencing of the bronchial biopsies was funded by Genentech (San Francisco, CA, USA). The author would like to thank Arnau Vich Vila (University of Groningen, Groningen, The Netherlands) for his scientific input regarding the development of the RNA-seq analysis pipeline in this study.

Keywords

bronchial biopsy
ClinicalTrials.gov Identifiers: NCT00158847
COPD
metatranscriptomics
microbiome

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1080/15412555.2022.2033193Licence: CC BY

Cite this

Ditz, B., Boekhoudt, J., Couto, N., Brandsma, C. A., Hiemstra, P. S., Tew, G. W., Neighbors, M., Grimbaldeston, M. A., Timens, W., Kerstjens, H. A. M., Rossen, J. W. A., Guryev, V., van den Berge, M., & Faiz, A. (2022). The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach. COPD: Journal of Chronic Obstructive Pulmonary Disease, 19(1), 81-87. https://doi.org/10.1080/15412555.2022.2033193

Ditz, B, Boekhoudt, J, Couto, N, Brandsma, CA, Hiemstra, PS, Tew, GW, Neighbors, M, Grimbaldeston, MA, Timens, W, Kerstjens, HAM, Rossen, JWA, Guryev, V, van den Berge, M & Faiz, A 2022, 'The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 19, no. 1, pp. 81-87. https://doi.org/10.1080/15412555.2022.2033193

@article{976f268b5a6e4f9082f3495427053902,

title = "The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach",

abstract = "Current knowledge about the respiratory microbiome is mainly based on 16S ribosomal RNA gene sequencing. Newer sequencing approaches, such as metatranscriptomics, offer the technical ability to measure the viable microbiome response to environmental conditions such as smoking as well as to explore its functional role by investigating host-microbiome interactions. However, knowledge about its feasibility in respiratory microbiome research, especially in lung biopsies, is still very limited. RNA sequencing was performed in bronchial biopsies from clinically stable smokers (n = 5) and ex-smokers (n = 6) with COPD not using (inhaled) steroids. The Trinity assembler was used to assemble non-human reads in order to allow unbiased taxonomical and microbial transcriptional analyses. Subsequently, host-microbiome interactions were analyzed based on associations with host transcriptomic data. Ultra-low levels of microbial mass (0.009%) were identified in the RNA-seq data. Overall, no differences were identified in microbiome diversity or transcriptional profiles of microbial communities or individual microbes between COPD smokers and ex-smokers in the initial test dataset as well as a larger replication dataset. We identified an upregulated host gene set, related to the simultaneous presence of Bradyrhizobium, Roseomonas, Brevibacterium.spp., which were related to PERK-mediated unfolded protein response (UPR) and expression of the microRNA-155-5p. Our results show that metatranscriptomic profiling in bronchial biopsy samples from stable COPD patients yields ultra-low levels of microbial mass. Further, this study illustrates the potential of using transcriptional profiling of the host and microbiome to gain more insight into their interaction in the airways.",

keywords = "bronchial biopsy, ClinicalTrials.gov Identifiers: NCT00158847, COPD, metatranscriptomics, microbiome",

author = "B. Ditz and J. Boekhoudt and N. Couto and Brandsma, {C. A.} and Hiemstra, {P. S.} and Tew, {G. W.} and M. Neighbors and Grimbaldeston, {M. A.} and W. Timens and Kerstjens, {H. A.M.} and Rossen, {J. W.A.} and V. Guryev and {van den Berge}, M. and A. Faiz",

note = "Funding Information: HK reports unrestricted grants, from Boehringer Ingelheim, Novartis and GlaxoSmithKline. He also reports fees advisory board participation for AstraZeneca, Boehringer Ingelheim, Novartis and GlaxoSmithKline. All above paid to his institution. GWT reports and I am a full time employee of Genentech, Inc and hold stock and options in the Roche. PH reports grants from Boerhinger Ingelheim, grants from Galapagos, outside the submitted work; MAG reports I am full time employee of Genentech, Inc and hold stock and options in the Roche Group. WT reports personal fees from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, personal fees from Bristol-Myers-Squibb, personal fees from AbbVie, outside the submitted work. JR reports personal fees from IDbyDNA Inc., from null, from null, outside the submitted work; and Dr. Rossen is currently an employee of IDbyDNA. IDbyDNA did not have any influence on the interpretation of reviewed data and conclusions drawn, nor on the drafting of the manuscript, and did not (financial) support the study. MN reports I am a full time employee of Genentech, Inc and hold stock and options in the Roche Group. BD, JB, NC, CAB, VG, AF and MvdB have nothing to disclose. Funding Information: The submitted work is cofinanced by the Ministry of Economic Affairs and Climate Policy by means of the PPP. AF was supported by a junior longfond grant (4.2.16.132JO). The study was funded by unrestricted grants from the Stichting Astma Bestrijding, the Netherlands Asthma Foundation, Netherlands Organization for Scientific Research (ZonMw), GlaxoSmithKline, the Royal Dutch Academy of Sciences and Arts, the University Medical Center Groningen and Leiden University Medical Center and the NIH R01 HL095388 (Spira/Lenburg). RNA-sequencing of the bronchial biopsies was funded by Genentech (San Francisco, CA, USA). The author would like to thank Arnau Vich Vila (University of Groningen, Groningen, The Netherlands) for his scientific input regarding the development of the RNA-seq analysis pipeline in this study. ",

year = "2022",

month = dec,

day = "31",

doi = "10.1080/15412555.2022.2033193",

language = "English",

volume = "19",

pages = "81--87",

journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",

issn = "1541-2555",

publisher = "Taylor and Francis",

number = "1",

}

TY - JOUR

T1 - The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach

AU - Ditz, B.

AU - Boekhoudt, J.

AU - Couto, N.

AU - Brandsma, C. A.

AU - Hiemstra, P. S.

AU - Tew, G. W.

AU - Neighbors, M.

AU - Grimbaldeston, M. A.

AU - Timens, W.

AU - Kerstjens, H. A.M.

AU - Rossen, J. W.A.

AU - Guryev, V.

AU - van den Berge, M.

AU - Faiz, A.

N1 - Funding Information: HK reports unrestricted grants, from Boehringer Ingelheim, Novartis and GlaxoSmithKline. He also reports fees advisory board participation for AstraZeneca, Boehringer Ingelheim, Novartis and GlaxoSmithKline. All above paid to his institution. GWT reports and I am a full time employee of Genentech, Inc and hold stock and options in the Roche. PH reports grants from Boerhinger Ingelheim, grants from Galapagos, outside the submitted work; MAG reports I am full time employee of Genentech, Inc and hold stock and options in the Roche Group. WT reports personal fees from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, personal fees from Bristol-Myers-Squibb, personal fees from AbbVie, outside the submitted work. JR reports personal fees from IDbyDNA Inc., from null, from null, outside the submitted work; and Dr. Rossen is currently an employee of IDbyDNA. IDbyDNA did not have any influence on the interpretation of reviewed data and conclusions drawn, nor on the drafting of the manuscript, and did not (financial) support the study. MN reports I am a full time employee of Genentech, Inc and hold stock and options in the Roche Group. BD, JB, NC, CAB, VG, AF and MvdB have nothing to disclose. Funding Information: The submitted work is cofinanced by the Ministry of Economic Affairs and Climate Policy by means of the PPP. AF was supported by a junior longfond grant (4.2.16.132JO). The study was funded by unrestricted grants from the Stichting Astma Bestrijding, the Netherlands Asthma Foundation, Netherlands Organization for Scientific Research (ZonMw), GlaxoSmithKline, the Royal Dutch Academy of Sciences and Arts, the University Medical Center Groningen and Leiden University Medical Center and the NIH R01 HL095388 (Spira/Lenburg). RNA-sequencing of the bronchial biopsies was funded by Genentech (San Francisco, CA, USA). The author would like to thank Arnau Vich Vila (University of Groningen, Groningen, The Netherlands) for his scientific input regarding the development of the RNA-seq analysis pipeline in this study.

PY - 2022/12/31

Y1 - 2022/12/31

N2 - Current knowledge about the respiratory microbiome is mainly based on 16S ribosomal RNA gene sequencing. Newer sequencing approaches, such as metatranscriptomics, offer the technical ability to measure the viable microbiome response to environmental conditions such as smoking as well as to explore its functional role by investigating host-microbiome interactions. However, knowledge about its feasibility in respiratory microbiome research, especially in lung biopsies, is still very limited. RNA sequencing was performed in bronchial biopsies from clinically stable smokers (n = 5) and ex-smokers (n = 6) with COPD not using (inhaled) steroids. The Trinity assembler was used to assemble non-human reads in order to allow unbiased taxonomical and microbial transcriptional analyses. Subsequently, host-microbiome interactions were analyzed based on associations with host transcriptomic data. Ultra-low levels of microbial mass (0.009%) were identified in the RNA-seq data. Overall, no differences were identified in microbiome diversity or transcriptional profiles of microbial communities or individual microbes between COPD smokers and ex-smokers in the initial test dataset as well as a larger replication dataset. We identified an upregulated host gene set, related to the simultaneous presence of Bradyrhizobium, Roseomonas, Brevibacterium.spp., which were related to PERK-mediated unfolded protein response (UPR) and expression of the microRNA-155-5p. Our results show that metatranscriptomic profiling in bronchial biopsy samples from stable COPD patients yields ultra-low levels of microbial mass. Further, this study illustrates the potential of using transcriptional profiling of the host and microbiome to gain more insight into their interaction in the airways.

AB - Current knowledge about the respiratory microbiome is mainly based on 16S ribosomal RNA gene sequencing. Newer sequencing approaches, such as metatranscriptomics, offer the technical ability to measure the viable microbiome response to environmental conditions such as smoking as well as to explore its functional role by investigating host-microbiome interactions. However, knowledge about its feasibility in respiratory microbiome research, especially in lung biopsies, is still very limited. RNA sequencing was performed in bronchial biopsies from clinically stable smokers (n = 5) and ex-smokers (n = 6) with COPD not using (inhaled) steroids. The Trinity assembler was used to assemble non-human reads in order to allow unbiased taxonomical and microbial transcriptional analyses. Subsequently, host-microbiome interactions were analyzed based on associations with host transcriptomic data. Ultra-low levels of microbial mass (0.009%) were identified in the RNA-seq data. Overall, no differences were identified in microbiome diversity or transcriptional profiles of microbial communities or individual microbes between COPD smokers and ex-smokers in the initial test dataset as well as a larger replication dataset. We identified an upregulated host gene set, related to the simultaneous presence of Bradyrhizobium, Roseomonas, Brevibacterium.spp., which were related to PERK-mediated unfolded protein response (UPR) and expression of the microRNA-155-5p. Our results show that metatranscriptomic profiling in bronchial biopsy samples from stable COPD patients yields ultra-low levels of microbial mass. Further, this study illustrates the potential of using transcriptional profiling of the host and microbiome to gain more insight into their interaction in the airways.

KW - bronchial biopsy

KW - ClinicalTrials.gov Identifiers: NCT00158847

KW - COPD

KW - metatranscriptomics

KW - microbiome

UR - http://www.scopus.com/inward/record.url?scp=85124353562&partnerID=8YFLogxK

U2 - 10.1080/15412555.2022.2033193

DO - 10.1080/15412555.2022.2033193

M3 - Article

C2 - 35118915

AN - SCOPUS:85124353562

SN - 1541-2555

VL - 19

SP - 81

EP - 87

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

IS - 1

ER -

The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this